Print this page
18 / Jul 03

Media Relations - ENYO Pharma raises €40 million

ENYO Pharma, a clinical stage biotech company developing innovative drug candidates by mimicking virus strategies to modulate host cellular functions, announced that it has completed a €40 million Series B round of financing from US and European investors. This new funding will enable the company to finance the two first Phase II clinical trial of its EYP001 asset in both chronic HBV and NASH. A second asset is also planned to enter clinic by 2019.